Your browser doesn't support javascript.
loading
Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis.
Coimbra, Susana; Rocha, Susana; Nascimento, Henrique; Valente, Maria João; Catarino, Cristina; Rocha-Pereira, Petronila; Sameiro-Faria, Maria; Oliveira, José Gerardo; Madureira, José; Fernandes, João Carlos; Miranda, Vasco; Belo, Luís; Bronze-da-Rocha, Elsa; Santos-Silva, Alice.
  • Coimbra S; UCIBIO/REQUIMTE, Porto, Portugal.
  • Rocha S; CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Gandra-Paredes, Portugal.
  • Nascimento H; LAQV/REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • Valente MJ; UCIBIO/REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • Catarino C; Neurology Service, University Hospital Centre, Porto, Portugal.
  • Rocha-Pereira P; UCIBIO/REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • Sameiro-Faria M; UCIBIO/REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • Oliveira JG; UCIBIO/REQUIMTE, Porto, Portugal.
  • Madureira J; Health Science Research Centre, University of Beira Interior, Covilhã, Portugal.
  • Fernandes JC; UCIBIO/REQUIMTE, Porto, Portugal.
  • Miranda V; Hemodialysis Clinic Hospital Agostinho Ribeiro, Felgueiras, Portugal.
  • Belo L; Hemodialysis Clinic of Porto (CHP), Porto, Portugal.
  • Bronze-da-Rocha E; Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal.
  • Santos-Silva A; NefroServe, Hemodialysis Clinic of Barcelos, Barcelos, Portugal.
Clin Kidney J ; 14(5): 1371-1378, 2021 May.
Article en En | MEDLINE | ID: mdl-33959266
ABSTRACT

BACKGROUND:

DNA damage and inflammation are common in end-stage renal disease (ESRD). Our aim was to evaluate the levels of circulating cell-free DNA (cfDNA) and the relationship with inflammation, anaemia, oxidative stress and haemostatic disturbances in ESRD patients on dialysis. By performing a 1-year follow-up study, we also aimed to evaluate the predictive value of cfDNA for the outcome of ESRD patients.

METHODS:

A total of 289 ESRD patients on dialysis were enrolled in the study we evaluated cfDNA, haemogram, serum iron, hepcidin, inflammatory and oxidative stress markers, and haemostasis. Events and causes of deaths were recorded throughout the follow-up period.

RESULTS:

ESRD patients, as compared with controls, presented significantly higher levels of cfDNA, hepcidin, and inflammatory and oxidative stress markers, and significantly lower values of iron and anaemia-related haemogram parameters. The all-cause mortality rate was 9.7%; compared with alive patients, deceased patients (n = 28) were older and presented significantly higher values of inflammatory markers and of cfDNA, which was almost 2-fold higher. Furthermore, cfDNA was the best predictor of all-cause mortality and cardiovascular mortality in ESRD patients, in both unadjusted and adjusted models for basic confounding factors in dialysis.

CONCLUSIONS:

Our data show cfDNA to be a valuable predictive marker of prognosis in ESRD patients on dialysis treatment; high levels of cfDNA were associated with a poor outcome.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article